| 货号 | KPTX188 |
|---|---|
| 品牌 | ProteoGenix |
| 样本类型 | Plasma, Serum |
| 检测范围 | 1.5625 ng/mL — 100 ng/mL |
| 保存溶液 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 检测方法 | Colorimetric |
| 实验类型 | Quantitative |
| 回收率 | 80-120% |
| 运输 | 2-8 ℃ |
| 规格 | Brolucizumab |
| 别名 | ESBA-1008, ESBA1008, RTH258, CAS: 1531589-13-5 |
| 背景 | Brolucizumab is the first and only single-chain variable fragment (scFv) targeting vascular endothelial growth factor (VEGF)-A. It has a smaller molecular weight (26 kDa). The mAb is undergoing evaluation as a treatment for neovascular age-related macular degeneration (nAMD). In June 2017, Novartis announced that the primary efficacy endpoint of non-inferiority to aflibercept (EYLEA®) in mean change in best-corrected visual acuity from baseline to week 48 was met in the Phase 3 HAWK (NCT02307682) and HARRIER (NCT02434328) studies, which included more than 1,800 patients. The two studies compared the efficacy and safety of intravitreal injections of 6 mg brolucizumab or 3 mg brolucizumab (HAWK study only) versus 2 mg aflibercept in patients with nAMD. Of patients receiving 6 mg brolucizumab, 57% (HAWK) and 52% (HARRIER) were maintained exclusively on an every 12 week dosing interval immediately following the loading phase and continuing through week 48.54 Key secondary endpoints were also met. Novartis is developing a competitive, low cost of goods formulation, and expects to complete the PK study with antibody derived from the final manufacturing process to enable filing in 2018. |
| Note | For Research Use Only. |
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
